Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19)

Detalhes bibliográficos
Autor(a) principal: Kislaya, I
Data de Publicação: 2021
Outros Autores: Gonçalves, P, Barreto, M, Sousa, R, Garcia, AC, Matos, R, Guiomar, R, Rodrigues, AP, Dias, A
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.17/3653
Resumo: Introduction: The aim of this study was to estimate and describe the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific antibodies (immunoglobulin M and/or immunoglobulin G) in Portugal in May-July 2020. Material and methods: A cross-sectional seroepidemiological survey was developed after the peak of the first epidemic wave on a sample of 2301 Portuguese residents, aged 1 year or older. Survey sample was selected using a two-stage stratified non-probability sampling design (quota sampling). SARS-CoV-2 immunoglobulin M and immunoglobulin G antibodies were measured in serum samples by enzyme-linked immunosorbent assay. Seroprevalence estimates of immunoglobulin M and/or immunoglobulin G and 95% confidence intervals were stratified by sex, age group, health region and education. Results: Overall, seroprevalence was 2.9% (95% confidence interval: 2.0% - 4.2%). Higher prevalence rates were observed in male (4.1%, 95% confidence interval: 2.6% - 6.6%) and those with secondary education (6.4%, 95% confidence interval: 3.2% - 12.5%). Differences in seroprevalence by age group and region were not statistically significant. Discussion: The estimated seroprevalence of SARS-CoV-2 was higher than the cumulative incidence reported by the National Surveillance System but far from necessary to reach herd immunity. Conclusion: Our results support limited extent of infection by SARS-CoV-2 in the study population possibly due to early lockdown measures implemented in Portugal and support the need to continue monitoring of SARS-CoV-2 seroprevalence in order to increase our knowledge about the evolution of the epidemic and to estimate the proportion of the susceptible population over time.
id RCAP_22f8297c050240e1587ea55c6faef0e1
oai_identifier_str oai:repositorio.chlc.min-saude.pt:10400.17/3653
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19)Seroprevalência da Infecção por SARS-CoV-2 em Portugal em Maio-Julho de 2020: Resultados do Primeiro Inquérito Serológico Nacional (ISNCOVID-19)AdolescentAdultAge DistributionAgedAntibodies, ViralCOVID-19ChildChild, PreschoolConfidence IntervalsCross-Sectional StudiesEducational StatusEpidemicsFemaleHumansImmunoglobulin GImmunoglobulin MInfantInfant, NewbornMaleMiddle AgedPortugalPrevalenceSARS-CoV-2Seroepidemiologic StudiesSex DistributionYoung AdultHDE PEDIntroduction: The aim of this study was to estimate and describe the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific antibodies (immunoglobulin M and/or immunoglobulin G) in Portugal in May-July 2020. Material and methods: A cross-sectional seroepidemiological survey was developed after the peak of the first epidemic wave on a sample of 2301 Portuguese residents, aged 1 year or older. Survey sample was selected using a two-stage stratified non-probability sampling design (quota sampling). SARS-CoV-2 immunoglobulin M and immunoglobulin G antibodies were measured in serum samples by enzyme-linked immunosorbent assay. Seroprevalence estimates of immunoglobulin M and/or immunoglobulin G and 95% confidence intervals were stratified by sex, age group, health region and education. Results: Overall, seroprevalence was 2.9% (95% confidence interval: 2.0% - 4.2%). Higher prevalence rates were observed in male (4.1%, 95% confidence interval: 2.6% - 6.6%) and those with secondary education (6.4%, 95% confidence interval: 3.2% - 12.5%). Differences in seroprevalence by age group and region were not statistically significant. Discussion: The estimated seroprevalence of SARS-CoV-2 was higher than the cumulative incidence reported by the National Surveillance System but far from necessary to reach herd immunity. Conclusion: Our results support limited extent of infection by SARS-CoV-2 in the study population possibly due to early lockdown measures implemented in Portugal and support the need to continue monitoring of SARS-CoV-2 seroprevalence in order to increase our knowledge about the evolution of the epidemic and to estimate the proportion of the susceptible population over time.Centro Editor Livreiro da Ordem dos MédicosRepositório do Centro Hospitalar Universitário de Lisboa Central, EPEKislaya, IGonçalves, PBarreto, MSousa, RGarcia, ACMatos, RGuiomar, RRodrigues, APDias, A2021-04-14T18:43:58Z2021-02-012021-02-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.17/3653porActa Med Port 2021 Feb;34(2):87-9410.20344/amp.15122info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-03-10T09:43:53Zoai:repositorio.chlc.min-saude.pt:10400.17/3653Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:20:57.253892Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19)
Seroprevalência da Infecção por SARS-CoV-2 em Portugal em Maio-Julho de 2020: Resultados do Primeiro Inquérito Serológico Nacional (ISNCOVID-19)
title Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19)
spellingShingle Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19)
Kislaya, I
Adolescent
Adult
Age Distribution
Aged
Antibodies, Viral
COVID-19
Child
Child, Preschool
Confidence Intervals
Cross-Sectional Studies
Educational Status
Epidemics
Female
Humans
Immunoglobulin G
Immunoglobulin M
Infant
Infant, Newborn
Male
Middle Aged
Portugal
Prevalence
SARS-CoV-2
Seroepidemiologic Studies
Sex Distribution
Young Adult
HDE PED
title_short Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19)
title_full Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19)
title_fullStr Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19)
title_full_unstemmed Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19)
title_sort Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19)
author Kislaya, I
author_facet Kislaya, I
Gonçalves, P
Barreto, M
Sousa, R
Garcia, AC
Matos, R
Guiomar, R
Rodrigues, AP
Dias, A
author_role author
author2 Gonçalves, P
Barreto, M
Sousa, R
Garcia, AC
Matos, R
Guiomar, R
Rodrigues, AP
Dias, A
author2_role author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório do Centro Hospitalar Universitário de Lisboa Central, EPE
dc.contributor.author.fl_str_mv Kislaya, I
Gonçalves, P
Barreto, M
Sousa, R
Garcia, AC
Matos, R
Guiomar, R
Rodrigues, AP
Dias, A
dc.subject.por.fl_str_mv Adolescent
Adult
Age Distribution
Aged
Antibodies, Viral
COVID-19
Child
Child, Preschool
Confidence Intervals
Cross-Sectional Studies
Educational Status
Epidemics
Female
Humans
Immunoglobulin G
Immunoglobulin M
Infant
Infant, Newborn
Male
Middle Aged
Portugal
Prevalence
SARS-CoV-2
Seroepidemiologic Studies
Sex Distribution
Young Adult
HDE PED
topic Adolescent
Adult
Age Distribution
Aged
Antibodies, Viral
COVID-19
Child
Child, Preschool
Confidence Intervals
Cross-Sectional Studies
Educational Status
Epidemics
Female
Humans
Immunoglobulin G
Immunoglobulin M
Infant
Infant, Newborn
Male
Middle Aged
Portugal
Prevalence
SARS-CoV-2
Seroepidemiologic Studies
Sex Distribution
Young Adult
HDE PED
description Introduction: The aim of this study was to estimate and describe the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific antibodies (immunoglobulin M and/or immunoglobulin G) in Portugal in May-July 2020. Material and methods: A cross-sectional seroepidemiological survey was developed after the peak of the first epidemic wave on a sample of 2301 Portuguese residents, aged 1 year or older. Survey sample was selected using a two-stage stratified non-probability sampling design (quota sampling). SARS-CoV-2 immunoglobulin M and immunoglobulin G antibodies were measured in serum samples by enzyme-linked immunosorbent assay. Seroprevalence estimates of immunoglobulin M and/or immunoglobulin G and 95% confidence intervals were stratified by sex, age group, health region and education. Results: Overall, seroprevalence was 2.9% (95% confidence interval: 2.0% - 4.2%). Higher prevalence rates were observed in male (4.1%, 95% confidence interval: 2.6% - 6.6%) and those with secondary education (6.4%, 95% confidence interval: 3.2% - 12.5%). Differences in seroprevalence by age group and region were not statistically significant. Discussion: The estimated seroprevalence of SARS-CoV-2 was higher than the cumulative incidence reported by the National Surveillance System but far from necessary to reach herd immunity. Conclusion: Our results support limited extent of infection by SARS-CoV-2 in the study population possibly due to early lockdown measures implemented in Portugal and support the need to continue monitoring of SARS-CoV-2 seroprevalence in order to increase our knowledge about the evolution of the epidemic and to estimate the proportion of the susceptible population over time.
publishDate 2021
dc.date.none.fl_str_mv 2021-04-14T18:43:58Z
2021-02-01
2021-02-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.17/3653
url http://hdl.handle.net/10400.17/3653
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv Acta Med Port 2021 Feb;34(2):87-94
10.20344/amp.15122
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Centro Editor Livreiro da Ordem dos Médicos
publisher.none.fl_str_mv Centro Editor Livreiro da Ordem dos Médicos
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799131305750822912